The Effects of Ezh2 Mutation on Kras-Driven Adenocarcinoma

被引：0
|
作者：
Mandias, Hannah [1 ]
Mao, Suifang [2 ]
Xue, Bin [2 ]
Fuziwara, Cesar [2 ]
He, Lin [2 ]
机构：
[1] Calif State Univ Long Beach, Long Beach, CA 90840 USA
[2] Univ Calif Berkeley, Berkeley, CA 94720 USA
来源：
FASEB JOURNAL | 2020年 / 34卷
基金：
美国国家科学基金会;
关键词：
D O I：
10.1096/fasebj.2020.34.s1.03039
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
    Wang, Yanxiao
    Hou, Ning
    Cheng, Xuan
    Zhang, Jishuai
    Tan, Xiaohong
    Zhang, Chong
    Tang, Yuling
    Teng, Yan
    Yang, Xiao
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2017, 13 (05): : 652 - 659
  • [2] Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
    Serresi, Michela
    Siteur, Bjorn
    Hulsman, Danielle
    Company, Carlos
    Schmitt, Matthias J.
    Lieftink, Cor
    Morris, Ben
    Cesaroni, Matteo
    Proost, Natalie
    Beijersbergen, Roderick L.
    van Lohuizen, Maarten
    Gargiulo, Gaetano
    JOURNAL OF EXPERIMENTAL MEDICINE, 2018, 215 (12): : 3115 - 3135
  • [3] KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
    Than, Minh T.
    O'Hara, Mark
    Stanger, Ben Z.
    Reiss, Kim A.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (10) : 1378 - 1388
  • [4] Neoadjuvant Ezh2 inhibition amplifies an inflammatory program and sensitizes Kras-driven NSCLC to anti-NF-κB inhibition
    Serresi, Michela
    Siteur, Bjorn
    Cesaroni, Matteo
    Proost, Natalie
    Hulsman, Danielle
    van Lohuizen, Maarten
    Gargiulo, Gaetano
    CANCER RESEARCH, 2016, 76
  • [5] Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
    Pan, Jing
    Zhang, Qi
    Sei, Shizuko
    Shoemaker, Robert H.
    Lubet, Ronald A.
    Wang, Yian
    You, Ming
    ONCOTARGET, 2017, 8 (47) : 82689 - 82699
  • [6] Neoadjuvant-like Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and creates new therapeutic vulnerabilities.
    Gargiulo, Gaetano
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 48 - 49
  • [7] Immunoprevention of KRAS-driven lung adenocarcinoma by a multi-peptide KRAS vaccine
    Pan, Jing
    Zhang, Qi
    Sei, Shizuko
    Shoemaker, Robert H.
    Lubet, Ronald A.
    Wang, Yian
    You, Ming
    CANCER RESEARCH, 2017, 77
  • [8] Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma
    Stephanie R. Hyslop
    Marliese Alexander
    Alesha A. Thai
    Ariena Kersbergen
    Andrew J. Kueh
    Marco J. Herold
    Jason Corbin
    Pradnya Gangatirkar
    Ashley P. Ng
    Benjamin J. Solomon
    Warren S. Alexander
    Kate D. Sutherland
    Emma C. Josefsson
    Oncogene, 2020, 39 : 5177 - 5186
  • [9] EZH2 MUTATION IN FOLLICULAR LYMPHOMA
    O' Riain, C.
    Smith, P.
    Clear, A.
    Wrench, D.
    Gupta, M.
    Boedoer, C.
    Matolcsy, A.
    Calaminici, M.
    Ouentmeier, H.
    Drexler, H.
    Young, B.
    Gribben, J.
    Lister, A.
    Fitzgibbon, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 167 - 167
  • [10] Separate and combined effects of caloric restriction mimetics and autophagy inhibition on KRAS-driven pancreatic adenocarcinoma
    Chen, Xuewen
    O'Flanagan, Ciara H.
    Coleman, Michael
    Der, Channing J.
    Hursting, Stephen D.
    CANCER RESEARCH, 2018, 78 (13)
12345